Health Protection - Creutzfeldt-Jakob Disease (CJD)
What is CJD?
Creutzfeldt-Jakob Disease (CJD) in its classical form was first described
in the 1920s and is predominantly (85% of cases) a sporadic disease, with no identifiable cause. It
is a rare disease and occurs worldwide at a similar rate of about 0.5 – 1 case per million of the population
per year. Approximately 14% of cases are associated with gene mutations (known as familial CJD). Less
than 1% of cases are iatrogenic (accidentally transmitted from one patient to another as a result of
medical interventions). In sporadic cases the average age at onset is between 55 and 75, although younger
patients are found in iatrogenic and familial cases.
In 1996 the National CJD Surveillance Unit in Edinburgh identified a
previously unrecognised disease pattern, New Variant CJD, now known just as Variant CJD (vCJD). vCJD
is a similar neuro-degenerative disease to CJD, however, the peak incidence is much lower (around age
27) and at post mortem examination the brain tissue displays a significantly different pattern under
the microscope.
Frequently asked questions
Statistics on the numbers of cases of CJD are published monthly
Department of Health monthly figures
Expert Committees
A number of expert committees
provide advice to
the Department on CJD and BSE issues including:
- Spongiform Encephalopathy Advisory Committee.
- Joint Working Group.
- CJD Incidents Panel.
- CJD Therapy Advisory Group.
Guidance documents and professional letters
For more information go to the Department of Health guidance
documents
.
21st May 2001
Guidance on local reporting of Creutzfeldt-Jakob Disease (CJD) and local
action by Consultants in Communicable Disease Control (CsCDC).
This document describes a system for reporting cases of CJD to Consultants
in Communicable Disease Control and their equivalents in the UK.
9th April 2001
Protocol for the investigation of Geographically Associated Cases of
variant Creutzfeldt-Jakob Disease.
This document describes a system for investigating geographically associated
cases of vCJD.
24th January 2001
November 2000
April 2000
Variant Creutzfeldt-Jakob Disease (vCJD): Advice to Practitioners of
Complementary and Alternative Medicine.
9th November 1999
- HSS(MD)16/99. Controls Assurance in Infection Control: Decontamination of medical devices.
13th August 1999
BSE, (Bovine Spongiform Encephalopathy), Background and general occupational guidance
Advisory Committee on Dangerous Pathogens HSE, 1996
ISBN 0 7176 1212 0
Price: £5.50
ISBN 0 7176 1212 0
Price: £5.50
Transmissible Spongiform Encephalopathies – a summary of present knowledge and research
Spongiform Encephalopathy Advisory Committee
MSO 1995
ISBN 0 11 242 9874
£35.00
MSO 1995
ISBN 0 11 242 9874
£35.00
Precautions for work with human and animal Transmissible Spongiform Encephalopathies
Advisory Committee on Dangerous Pathogens
HMSO, 1994
ISBN 0 11 321805 2
Price £6.50.
HMSO, 1994
ISBN 0 11 321805 2
Price £6.50.

